Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
State Street Corporation, through its investment management subsidiaries, reports beneficial ownership of 9,964,151 shares of Vir Biotechnology, Inc. common stock, representing 5.9% of the class as of June 30, 2026. All voting and dispositive authority is held on a shared basis, with 9,678,303 shares subject to shared voting power and 9,964,151 shares subject to shared dispositive power; there is no sole voting or dispositive power. The position is held across affiliated investment advisers including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd. No group or other person is identified as having more than 5% economic interest apart from these affiliated entities.
Vir Biotechnology, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026, driven by a new collaboration with Astellas. Total revenues were $238,946 thousand, up from $1,214 thousand a year earlier, as the company recognized $239.3 million of license and collaboration revenue from the VIR‑5500 Astellas agreement. Net income reached $80,080, compared with a net loss of $110,958 in the prior‑year quarter, or $0.47 diluted earnings per share.
Research and development expenses rose to $135,283 thousand as Vir advanced its hepatitis delta ECLIPSE registrational program and multiple PRO‑XTEN dual‑masked T‑cell engager trials. A February 2026 follow‑on offering raised approximately $162.2 million, contributing to about $1.01 billion in cash, cash equivalents and investments as of June 30, 2026, which management believes is sufficient to fund operations for at least twelve months. Despite the profitable quarter, the company recorded a six‑month net loss of $45,615 while continuing to invest heavily in its infectious disease and oncology pipeline.
Vir Biotechnology, Inc. reported second quarter 2026 results highlighted by $238.9 million in total revenues, primarily license and collaboration revenue from a $240.0 million upfront payment from Astellas, and net income of $80.1 million, or $0.48 per share basic, versus a $111.0 million loss a year earlier.
Cash, cash equivalents and investments were approximately $1.01 billion as of June 30, 2026, after receiving a $75 million equity investment from Astellas and making a $48.0 million pass-through payment to Sanofi; this balance is expected to fund operations into the second half of 2028.
In chronic hepatitis delta, Phase 2 SOLSTICE data showed undetectable HDV RNA in 88% of combination-treated participants at Week 96, with 97% in a last-observation analysis and a generally well tolerated profile. The ECLIPSE registrational program is fully enrolled, with key Phase 3 data expected between late 2026 and early 2027, while the Astellas collaboration advances VIR-5500 and other PRO-XTEN T-cell engagers through multiple Phase 1 dose-expansion cohorts.
Vanguard Portfolio Management, on behalf of certain Vanguard-affiliated entities and managed accounts, reports beneficial ownership of 11,554,377 shares of Vir Biotechnology Inc common stock on an amended Schedule 13G. This represents 6.85% of the class as of June 30, 2026.
The filer has sole voting power over 59,162 shares and sole dispositive power over 11,554,377 shares, with no shared voting or dispositive power. The holdings include securities held by Vanguard funds and other clients over which the reporting entities exercise dispositive and/or voting power.
Vir Biotechnology, Inc. reports that Executive Vice President and Chief Financial Officer Jason O’Byrne informed the company on July 20, 2026 that he will step down from his role effective August 3, 2026 to pursue another opportunity. The company states that his resignation is not due to any disagreement regarding operations, policies, or practices, and it has begun a search for a permanent successor.
On July 23, 2026, the Board appointed Brent Sabatini, CPA, MBA, currently Senior Vice President and Chief Accounting Officer, as interim principal financial officer, effective August 3, 2026. Sabatini, 52, has served as Vir’s Senior Vice President and Chief Accounting Officer since February 2023 and principal accounting officer since October 2024, and previously held finance leadership roles at Capsida Biotherapeutics and Amgen. He has no reportable related-party transactions, no special arrangements relating to his selection, no family relationships with directors or executives, and will receive no additional compensation for the interim role.
Vir Biotechnology, Inc. director Timothy Coughlin reported compensation-related equity grants. He acquired two awards of 8,000 shares of common stock each at no cost, in the form of restricted stock units under the company’s Equity Incentive Plan. He also received two stock option grants covering 16,000 shares each at an exercise price of $8.51 per share, expiring in 2036. Portions of the RSUs and options begin vesting on June 9, 2027, with remaining amounts vesting over time or in full by the earlier of that date or the next annual meeting of stockholders. Following these grants, one reported common stock position shows 16,000 shares held directly.
Vir Biotechnology, Inc. director Timothy Coughlin filed an initial Form 3 reporting his beneficial ownership of the company’s common stock. The filing shows he directly owns 0 shares of common stock following the reported position as of June 9, 2026.
Vir Biotechnology, Inc. announced that its Board of Directors increased in size from seven to eight members and appointed Timothy Coughlin, CPA, as a new Class III director effective June 9, 2026. He will serve on the Board until the company’s 2028 annual meeting of stockholders.
Coughlin was also appointed as Chair of the Audit Committee, giving him a key oversight role in the company’s financial reporting. He was not selected pursuant to any arrangement with another person, and the company reports no related party transactions requiring disclosure.
As a non-employee director, Coughlin will receive standard cash and equity compensation under Vir’s non-employee director compensation policy. On his appointment date, he received stock option and restricted stock unit awards under the company’s 2019 Equity Incentive Plan, and he entered into Vir’s standard indemnity agreement for directors.
Vir Biotechnology director Janet Napolitano sold 3,200 shares of Common Stock in an open-market transaction at $9.45 per share. After the sale, she directly holds 21,216 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 27, 2025.